Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/9/2024 | $70.00 | Mkt Outperform | JMP Securities |
| 7/8/2024 | $90.00 | Buy | BTIG Research |
| 6/27/2024 | $86.00 | Buy | Stifel |
| 5/6/2024 | $65.00 | Buy | H.C. Wainwright |
| 4/3/2024 | $65.00 | Outperform | Evercore ISI |
| 3/28/2024 | $70.00 | Outperform | RBC Capital Mkts |
| 3/18/2024 | Outperform | TD Cowen | |
| 8/11/2023 | $7.00 | Overweight | CapitalOne |
JMP Securities initiated coverage of Jasper Therapeutics with a rating of Mkt Outperform and set a new price target of $70.00
BTIG Research initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $90.00
Stifel initiated coverage of Jasper Therapeutics with a rating of Buy and set a new price target of $86.00
14 of 15 participants enrolled achieved a clinical response 10 of 12 participants in the 120mg cohort achieved a complete response No serious adverse events; no grade 3 or higher adverse events reported Initial data from BEACON study expected week of January 6th, 2025, including 180mg Q8W cohort Company to host conference call and webinar today at 8:00 a.m. EDT REDWOOD CITY, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic induci
8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
10-Q - Jasper Therapeutics, Inc. (0001788028) (Filer)
8-K - Jasper Therapeutics, Inc. (0001788028) (Filer)
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
3 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
REDWOOD CITY, Calif., June 19, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced the appointment of Svetlana Lucas, Ph.D., to Jasper's Board of Directors (the Board), effective as of June 18, 2024. Separately, Anna French, D. Phil., stepped down from the Board, effective as of June 18, 2024. "We are pleased to welcome Svetlana, an experienced and accomplished biopharmaceutical executive, to our B
REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), as well as lower to intermediate risk myelodysplastic syndromes (LR-MDS) and novel stem cell transplant conditioning regimens, today announced the appointment of Thomas G. Wiggans, a veteran biopharmaceutical executive, as Chairperson of Jasper's Board of Directors (the Board), effective immediately. Bill Lis is stepping down as Chairperson and will re
Patricia Carlos Appointed Senior Vice President of Regulatory Affairs and Quality Annette Marcantonio Appointed Vice President of Clinical Operations REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of two seasoned pharma industry executives to its regulatory affairs, quality and clinical operations
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
4 - Jasper Therapeutics, Inc. (0001788028) (Issuer)
SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
SC 13G/A - Jasper Therapeutics, Inc. (0001788028) (Subject)
BTIG analyst Justin Zelin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Buy rating and announces Price Target of $90.
REDWOOD CITY, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced that it will participate in the following investor conferences: Stifel 2024 Healthcare ConferenceConference Dates: November 18 – 19, 2024Presentation Date: Monday, November 18, 2024, 9:45 a.m. ETPresentation Format: Fireside Chat Jefferies London Healthcare Conference 2024Conference Dates: November 19-21, 2024 7th
REDWOOD CITY, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today reported results for the fiscal quarter ended September 30, 2024, provided a corporate update and announced the closure of Jasper's legacy clinical study in lower-risk myelodysplastic syndromes (LR-MDS). "We achieved several significant milestones in our mast cell development programs in recent months, highlighted by positive
REDWOOD CITY, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from preclinical studies evaluating briquilimab at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting, taking place October 24-28, 2024, in Boston, Massachusetts. "We are pleased to present promising preclinical results from multiple studies at ACAAI this year," said Wendy Pan